Published in World J Gastroenterol on February 28, 2015
Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget (2015) 0.78
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. J Gastrointest Oncol (2016) 0.78
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer (2016) 0.76
Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab. Case Rep Oncol (2016) 0.75
Uncertainty Abounds in the World of Anal Dysplasia Screening. Sex Transm Dis (2016) 0.75
Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. Sci Rep (2017) 0.75
No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy. Br J Cancer (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA (2008) 4.61
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol (2013) 3.56
Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer (2004) 3.40
Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum (1974) 2.86
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol (2012) 2.62
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol (2007) 2.44
Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie (2006) 1.90
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol (2012) 1.84
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer (1999) 1.70
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer (2010) 1.57
Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer (1984) 1.52
Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer (1967) 1.47
HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol (2008) 1.35
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst (1989) 1.34
Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg (2011) 1.28
Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg (2006) 1.28
Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology (2009) 1.27
Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys (2007) 1.23
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol (1998) 1.20
Squamous cell carcinoma of the anus at one hospital from 1948 to 1984. Br J Surg (1989) 1.19
Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. Int J Radiat Oncol Biol Phys (1993) 1.19
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med (1985) 1.19
Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol (2009) 1.13
Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol (2008) 1.12
Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur J Cancer (2000) 1.11
Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum (2007) 1.11
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer (2010) 1.10
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer (1999) 1.10
Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol (1996) 1.09
Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med (1989) 1.09
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 1.08
The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys (1999) 1.07
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys (2005) 1.04
Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum (2004) 1.03
Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. Am J Surg (2011) 1.01
Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol (2006) 1.01
K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol (2009) 1.01
Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol (2007) 1.01
Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. Am J Surg (1985) 1.00
Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. Cancer (1999) 0.99
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer (2012) 0.98
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys (2009) 0.97
Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) (2010) 0.96
Carcinoma of the anal canal: a study of 79 cases. Am J Clin Pathol (1985) 0.96
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol (2013) 0.96
Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum (2001) 0.96
Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark's Hospital 1928-66. Proc R Soc Med (1968) 0.94
Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Cancer (1995) 0.93
Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet (1985) 0.93
Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival. J Surg Oncol (2012) 0.91
Anal cancer with cerebral metastasis: a case report. J Neurooncol (2010) 0.91
Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol (1993) 0.91
Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys (2006) 0.91
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One (2014) 0.90
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol (2008) 0.89
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs (2006) 0.89
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer (2009) 0.89
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys (2013) 0.89
Malignant epithelial tumors of the anal canal. Cancer (1981) 0.89
Depth of invasion, location, and size of cancer of the anus dictate operative treatment. Cancer (1983) 0.85
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol (2010) 0.85
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer (2013) 0.85
Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. Case Rep Oncol (2012) 0.85
EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol (2013) 0.84
Management of anal cancer in the HIV-positive population. Oncology (Williston Park) (2005) 0.84
Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol (2012) 0.84
A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract (2011) 0.83
Treatment of relapsing anal carcinoma. Acta Oncol (1993) 0.83
Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum (2014) 0.81
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol (2013) 0.81
[Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - a case report]. Gan To Kagaku Ryoho (2012) 0.81
Photodynamic therapy for anal cancer. Photodiagnosis Photodyn Ther (2010) 0.79
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep (1986) 0.79
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res (2011) 0.79
Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals. Ann Surg Oncol (2013) 0.78
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. BMC Cancer (2011) 0.78
Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer. Anticancer Res (2011) 0.77
Anal squamous cell cancer nodal metastases: prognostic significance and therapeutic considerations. Surg Oncol Clin N Am (1996) 0.77
Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum (2007) 0.77
[Diagnosis and therapy for anal carcinoma]. Chirurg (2008) 0.76
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. J Oncol Pharm Pract (2014) 0.76
[A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. Gan To Kagaku Ryoho (2010) 0.76
External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients. Cancer Invest (2014) 0.76